10,455 Shares in Pfizer Inc. (NYSE:PFE) Acquired by Clarity Financial LLC

Clarity Financial LLC bought a new position in Pfizer Inc. (NYSE:PFE) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 10,455 shares of the biopharmaceutical company’s stock, valued at approximately $303,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. United Advisor Group LLC increased its holdings in Pfizer by 356.6% in the 3rd quarter. United Advisor Group LLC now owns 44,783 shares of the biopharmaceutical company’s stock worth $1,296,000 after acquiring an additional 34,976 shares in the last quarter. Cary Street Partners Asset Management LLC increased its holdings in Pfizer by 7.0% in the 3rd quarter. Cary Street Partners Asset Management LLC now owns 18,865 shares of the biopharmaceutical company’s stock worth $546,000 after acquiring an additional 1,238 shares in the last quarter. Greenwood Capital Associates LLC purchased a new stake in Pfizer in the 3rd quarter worth approximately $1,473,000. FSM Wealth Advisors LLC increased its holdings in Pfizer by 24.1% in the 3rd quarter. FSM Wealth Advisors LLC now owns 18,982 shares of the biopharmaceutical company’s stock worth $549,000 after acquiring an additional 3,688 shares in the last quarter. Finally, Moloney Securities Asset Management LLC increased its holdings in Pfizer by 37.8% in the 3rd quarter. Moloney Securities Asset Management LLC now owns 21,086 shares of the biopharmaceutical company’s stock worth $610,000 after acquiring an additional 5,785 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director Scott Gottlieb purchased 1,000 shares of the stock in a transaction that occurred on Wednesday, October 30th. The stock was bought at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the transaction, the director now directly owns 10,000 shares in the company, valued at $282,400. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 0.06% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a report on Wednesday, October 23rd. Evercore ISI raised shares of Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Sanford C. Bernstein assumed coverage on shares of Pfizer in a report on Thursday, October 17th. They set a “market perform” rating and a $32.00 price objective for the company. Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and increased their price objective for the company from $28.00 to $34.00 in a report on Wednesday, August 7th. Finally, StockNews.com raised shares of Pfizer from a “hold” rating to a “buy” rating in a report on Wednesday, October 9th. Eight investment analysts have rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $33.58.

Pfizer Stock Down 1.2 %

NYSE PFE opened at $27.76 on Tuesday. The company has a market capitalization of $157.31 billion, a P/E ratio of 37.51, a P/E/G ratio of 0.89 and a beta of 0.67. The stock has a 50 day moving average price of $29.01 and a 200-day moving average price of $28.63. Pfizer Inc. has a one year low of $25.20 and a one year high of $31.54. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. The company had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a return on equity of 16.40% and a net margin of 7.07%. Pfizer’s revenue was up 31.2% on a year-over-year basis. During the same period last year, the company earned ($0.17) earnings per share. As a group, equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be given a $0.42 dividend. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a yield of 6.05%. Pfizer’s dividend payout ratio is presently 227.03%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.